Eyepoint Pharmaceuticals Stock Alpha and Beta Analysis
| EYPT Stock | USD 8.95 0.60 7.19% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Eyepoint Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Eyepoint Pharmaceuticals over a specified time horizon. Remember, high Eyepoint Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Eyepoint Pharmaceuticals' market risk premium analysis include:
Beta 3.06 | Alpha (0.28) | Risk 5.82 | Sharpe Ratio (0) | Expected Return (0.01) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Eyepoint |
Eyepoint Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Eyepoint Pharmaceuticals market risk premium is the additional return an investor will receive from holding Eyepoint Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Eyepoint Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Eyepoint Pharmaceuticals' performance over market.| α | -0.28 | β | 3.06 |
Eyepoint Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Eyepoint Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Eyepoint Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Eyepoint Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Eyepoint Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Eyepoint Pharmaceuticals shares will generate the highest return on investment. By understating and applying Eyepoint Pharmaceuticals stock market price indicators, traders can identify Eyepoint Pharmaceuticals position entry and exit signals to maximize returns.
Eyepoint Pharmaceuticals Return and Market Media
The median price of Eyepoint Pharmaceuticals for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 9.0 with a coefficient of variation of 14.13. The daily time series for the period is distributed with a sample standard deviation of 1.34, arithmetic mean of 9.49, and mean deviation of 1.15. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Hassan Fred of 60000 shares of Eyepoint Pharmaceuticals at 8.16 subject to Rule 16b-3 | 09/03/2024 |
2 | Deerfield Management Company L.P. Series C Grows Stock Holdings in EyePoint Pharmaceuticals, Inc. - MarketBeat | 09/26/2024 |
3 | EyePoint Pharmaceuticals adds US78m to market cap in the past 7 days, though investors from five years ago are still down 62 | 10/15/2024 |
4 | EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 | 10/16/2024 |
5 | EyePoints Investigational Drug Shows Early And Sustained Improvement Than Regenerons Eylea For Diabetes-Associated Vision Loss | 10/28/2024 |
6 | Really competitive tax breaks keep EyePoint manufacturing in Mass. | 10/29/2024 |
7 | Vanguard Group Incs Strategic Acquisition in EyePoint Pharmaceuticals Inc | 11/05/2024 |
8 | EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments | 11/07/2024 |
9 | Wall Street Analysts See a 175.07 percent Upside in EyePoint Pharmaceuticals Can the Stock Really Move This High | 11/13/2024 |
10 | EYPT Enterprise Value 6.54 Mil - GuruFocus.com | 11/20/2024 |
About Eyepoint Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Eyepoint or other stocks. Alpha measures the amount that position in Eyepoint Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 181.36 | 136.67 | 6.39 | 6.07 | PTB Ratio | 1.91 | 1.36 | 3.29 | 3.13 |
Eyepoint Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Eyepoint Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eyepoint Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Eyepoint Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Eyepoint Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Eyepoint Pharmaceuticals' management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Eyepoint Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.